

AAPS PharmSci 360 - Poster Abstract Tracks (Subtracks) | Primary Topics | Keywords = (Review Groups)

There are four tracks covering all aspects of the pharmaceutical sciences. Three tracks are divided into two subtracks with Biomolecular and Chemical focuses. The Preclinical, Clinical, and Translational Sciences track is not split into subtracks.

IMPORTANT NOTE: In the submission site the structure below, Track (Subtrack), Primary Topic, and Keywords, are referred to as Review Groups. Screeners, please select all Review Groups that apply to your expertise.

Review Group Selection Process

1. Select the Track-Subtrack that best fits your research. (see below)

- * Preclinical, Clinical, and Translational Sciences
- * Bioanalytics
- * Manufacturing and Analytical Characterization
- * Formulation and Delivery

2. Select the Subtrack (Biomolecular or Chemical). Does not apply to the Preclinical, Clinical, and Translational Sciences track.

3. Select the Primary Topic that best fits your research.

4. From your Primary Topic, select the best Keywords for your research. If no listed Keywords fits your research, select 'Other'. (Note: In some instances there are no Keywords.)

TRACK (SUBTRACK)	PRIMARY TOPIC	KEYWORDS
Bioanalytics - Biomolecular	Analyte Stability	Ex Vivo In Vitro Solution
Bioanalytics - Biomolecular	Bioanalytical	New Applications of Existing Technology New Approaches New Technology
Bioanalytics - Biomolecular	Bioanalytical Innovations and Applications	n/a
Bioanalytics - Biomolecular	Bioanalytical Risk Assessment and Strategy	n/a
Bioanalytics - Biomolecular	Biology	Biomarkers Immunogenicity Biomarker/Pharmacodynamic Measurement Clinical Qualification Diagnostic Development (including companion diagnostics) Disease Heterogeneity Assessments Exosome Flow Cytometry Methods High Content Data Analysis Hybrid Methods (e.g. IP/LCMS) Imaging Methods Ligand Binding Assay (LBA) Methods Mass Spectrometry (LC-MS) Methods New Matrices New Modalities OMICs PCR Methods Preanalytical Variables Single-Cell-Based Biomarkers Target Engagement/Receptor Occupancy Vaccines
Bioanalytics - Biomolecular	Biomarker Quantification	
Bioanalytics - Biomolecular	Drug Quantification	Endogenous Homologs Quantification Flow Cytometry Methods Hybrid Methods (e.g. IP/LCMS) Imaging Methods Ligand Binding Assay (LBA) Methods Mass Spectrometry (LC-MS) Methods Other Methods/Techniques PCR Methods Post-marketing Commitment Surrogate Analyte Therapeutic Drug Monitoring
Bioanalytics - Biomolecular	Immunogenicity	Binding Antibody Methods Cell-Based Methodologies Immunogenicity Prediction Immunogenicity Risk Assessments Neutralizing Antibody Methods
Bioanalytics - Biomolecular	In Vivo and Ex Vivo Biotransformation	ADC Metabolism Evaluation of In Vivo Biotransformation Impact of Biotransformation on Immunogenicity Impact of Biotransformation on PK Molecule Variants Quantification Ex Vivo
Bioanalytics - Biomolecular	Life Cycle Management of Bioanalytical Methods	Collaboration with other Partners (Co-development) Data Management General Life Cycle Management Methods Transfer and CRO Management
Bioanalytics - Biomolecular	Novel Modalities	ADCs Alternative Scaffold CAR-T Cell-Based Therapy Encapsulated Drugs (Lipid, Nanoparticle, etc.) Multi-specific Antibodies Nanoparticle Based Modalities Oligos, RNAs, and Locked Nucleic Acids Other Viral Vectors

TRACK (SUBTRACK)	PRIMARY TOPIC	KEYWORDS
Bioanalytics - Biomolecular	Pharmacology	Bioanalytical Biomarkers
Bioanalytics - Biomolecular	Reagents and Reference Standards	Characterization and Quality Control Life Cycle Management Stability
Bioanalytics - Biomolecular	Regulations (BMV/GLP/GCP/CLIA)	Biomarkers Drug (and Metabolites) GCP/GLP Compliance for Bioanalytical Labs General Topics ICH and Harmonization Immunogenicity and Risk Assessment Samples and Reagent Stability
Bioanalytics - Biomolecular	Samples and Laboratory Management	Bioanalytical Documentation and Reports Biorepositories Informed Consent Laboratory Information Management System (LIMS) Patient-Centric Sampling (microsampling and dried blood Post-Collection Sample Condition and Record Management
Bioanalytics - Biomolecular	Vaccines	Binding Antibody Methods Cell-Based Methodologies Correlates of Protection Neutralizing Antibody Methods
Bioanalytics - Chemical	Analyte Stability	Ex Vivo In Vitro Solution
Bioanalytics - Chemical	Bioanalytical Innovations and Applications	n/a
Bioanalytics - Chemical	Bioanalytical Risk Assessment and Strategy	n/a
Bioanalytics - Chemical	Biomarker Quantification	Biomarker/Pharmacodynamic Measurement Clinical Qualification Diagnostic Development (including companion diagnostics) Disease Heterogeneity Assessments Exosome Flow Cytometry Methods High Content Data Analysis Hybrid Methods (e.g. IP/LCMS) Imaging Methods Ligand Binding Assay (LBA) Methods Mass Spectrometry (LC-MS) Methods New Matrices New Modalities OMICs PCR Methods Preanalytical Variables Single-Cell-Based Biomarkers Target Engagement/Receptor Occupancy
Bioanalytics - Chemical	Drug Quantification	Endogenous Homologs Quantification Flow Cytometry Methods Hybrid Methods (e.g. IP/LCMS) Imaging Methods Ligand Binding Assay (LBA) Methods Mass Spectrometry (LC-MS) Methods Other Methods/Techniques PCR Methods Post-marketing Commitment Surrogate Analyte Therapeutic Drug Monitoring
Bioanalytics - Chemical	Immunogenicity	Binding Antibody Methods Cell-Based Methodologies Immunogenicity Prediction Immunogenicity Risk Assessments Neutralizing Antibody Methods
Bioanalytics - Chemical	In Vivo and Ex Vivo Biotransformation	ADC Metabolism CYP450 Assessment Evaluation of In Vivo Biotransformation Impact of Biotransformation on Immunogenicity Impact of Biotransformation on PK Metabolite Quantification
Bioanalytics - Chemical	Life Cycle Management of Bioanalytical Methods	Collaboration with other Partners (Co-development) Data Management General Life Cycle Management Methods Transfer and CRO Management
Bioanalytics - Chemical	Medicinal Chemistry	Structure Activity Relationship
Bioanalytics - Chemical	Novel Modalities	ADCs Alternative Scaffold CAR-T Cell-Based Therapy Encapsulated Drugs (Lipid, Nanoparticle, etc.) Multi-specific Antibodies Nanoparticle Based Modalities Oligos, RNAs, and Locked Nucleic Acids Other Viral Vectors
Bioanalytics - Chemical	Reagents and Reference Standards	Characterization and Quality Control Life Cycle Management Stability

TRACK (SUBTRACK)	PRIMARY TOPIC	KEYWORDS
Bioanalytics - Chemical	Regulations (BMV/GLP/GCP/CLIA)	Biomarkers Drug (and Metabolites) GCP/GLP Compliance for Bioanalytical Labs General Topics ICH and Harmonization Immunogenicity and Risk Assessment Samples and Reagent Stability
Bioanalytics - Chemical	Samples and Laboratory Management	Bioanalytical Documentation and Reports Biorepositories Informed Consent Laboratory Information Management System (LIMS) Patient-Centric Sampling (microsampling and dried blood Post-Collection Sample Condition and Record Management
Formulation and Delivery - Biomolecular	Administration	DP Handling In-Use Compatibility Nasal/Pulmonary Ocular Other Otic Potent Modalities Sterility and Microbiology Strategies Transdermal
Formulation and Delivery - Biomolecular	Drug Delivery	Extended Release (Non-implant) Implants On Body Delivery Systems (OBDS) Other Other Routes of Administration - Ocular Other Routes of Administration - Other Other Routes of Administration - Otic Other Routes of Administration - Transdermal and Topical
Formulation and Delivery - Biomolecular	Drug Delivery, Devices, and Drug Device	Design Control Hardware Human Factor Engineering New Delivery Technologies Patient-Centric Development Software
Formulation and Delivery - Biomolecular	Formulation	Cell Therapy Free Oligonucleotide Gene Therapy Other Protein - Developability Assessment Protein - Excipients Protein - High-Throughput Screening Protein - Lyo Protein - Other Protein - Syringes Protein - Topics Vaccine/Tolerance Induction
Formulation and Delivery - Biomolecular	Pharmaceutics	Drug Delivery Novel Systems Drug Delivery Ocular Drug Delivery Transdermal Pharmaceutical Polymers
Formulation and Delivery - Biomolecular	Primary Packaging	Compatibility Container Closure Integrity Extractables/Leachables New Materials
Formulation and Delivery - Biomolecular	Regulatory Considerations	(Sub)visible Particles Accelerated Approval Pathways Bioequivalence Biosimilars Innovative Technologies Inspections and GMPs Large Market Developments New Regulations and Guidances Risk Assessment Implementation Smaller Market Developments Stability Requirements
Formulation and Delivery - Chemical	Biopharmaceutics	BCS, DCS Bioequivalence (also Regulatory) Comparability Assessments IVIVC Other Predictive Modeling
Formulation and Delivery - Chemical	Drug Delivery	Extended Release (Non-implant) Implants Nanoparticles Other Other Routes of Administration - Ocular Other Routes of Administration - Other Other Routes of Administration - Otic Other Routes of Administration - Transdermal and Topical
Formulation and Delivery - Chemical	Drug Delivery, Devices, and Drug Device	Design Control Hardware Human Factor Engineering

TRACK (SUBTRACK)	PRIMARY TOPIC	KEYWORDS
Formulation and Delivery - Chemical	Drug Delivery, Devices, and Drug Device	New Delivery Technologies Patient-Centric Development Software
Formulation and Delivery - Chemical	Formulation	Advanced Dissolution Testing Amorphous and Co-crystal Systems Bioavailability Enhancement Drug Substance Properties Excipients Fixed Dose Combinations Inhalation and Nasal Oral - Immediate Release Oral - Modified Release Parenterals Predictive Modeling Preformulation Special Populations
Formulation and Delivery - Chemical	Pharmaceutics	Drug Delivery Novel Systems Drug Delivery Ocular Drug Delivery Transdermal Pharmaceutical Polymers
Formulation and Delivery - Chemical	Primary Packaging	Compatibility Container Closure Integrity Extractables/Leachables New Materials
Formulation and Delivery - Chemical	Regulatory Considerations	(Sub)visible Particles Accelerated Approval Pathways Bioequivalence Biosimilars Innovative Technologies Inspections and GMPs Large Market Developments New Regulations and Guidances Patient Focused Drug Development Guidelines Risk Assessment Implementation Smaller Market Developments Stability Requirements
Manufacturing and Analytical Characterization - Biomolecular	Analytical	(Sub)visible Particles Combination Products Excipients Immunogenicity Impurities Modality Specific Methods - Cell Therapy Modality Specific Methods - Free Oligonucleotide Modality Specific Methods - Gene Therapy Modality Specific Methods - Other Modality Specific Methods - Protein Modality Specific Methods - Vaccine/Tolerance Induction New Technology Other Potency/Bioassay
Manufacturing and Analytical Characterization - Biomolecular	Automation	Computer Validation Other
Manufacturing and Analytical Characterization - Biomolecular	Biosimilar Manufacturing	Biosimilarity Assessment Other Patent Protection
Manufacturing and Analytical Characterization - Biomolecular	Drug Product Manufacturing and Development	Aseptic Technologies - Mixing, Sterilization, and Filling Cell Therapies Freezing and Thawing Immunogenicity and Critical Quality Attributes Lyophilization and Drying Technologies Manufacturing and Assembly of Drug/Device Combinations Manufacturing of Drug Delivery Systems Other Primary Packaging - Container Closure Integrity Primary Packaging - Other Primary Packaging - Syringes Primary Packaging - Vials Process Characterization and Optimization Protein Aggregation and Degradants Secondary Packaging Storage Considerations Vaccines Viral and Non-viral Vectors and Gene Therapy Visible and Subvisible Particles Visual Inspection
Manufacturing and Analytical Characterization - Biomolecular	Drug Substance Manufacturing and Development	API Packaging and Storage Cell Line Development Cell Therapies Clonality Assessments Expression Systems - Cellular and Cell-Free Genetic and Cell Line Engineering Mammalian Cell Culture Media Development Microbial/Yeast Fermentation Other

TRACK (SUBTRACK)	PRIMARY TOPIC	KEYWORDS
		Process Optimization and Intensification Protein Aggregation during Processing and Immunogenicity Purification and Virus Removal Vaccines Viral and Non-viral Vectors and Gene Therapy Virus Safety/Removal
Manufacturing and Analytical Characterization - Biomolecular	General Aspects and Strategies	Change Control CMO Management Drug Master Files Drug Substance and Drug Product Shipment Electronic Records Handling Control Substances (DEA) Inspections and GMP Lean Manufacturing/Six Sigma/Operational Excellence Life Cycle Management Manufacturing Economics Materials Management and Warehousing Other Regulatory Strategy Supply Chain
Manufacturing and Analytical Characterization - Biomolecular	Health, Safety, and Environment	Containment and Isolators High-Potent Drug Manufacturing OEL and PDE Other
Manufacturing and Analytical Characterization - Biomolecular	Innovative/Novel Processing Technologies and Concepts	For Use in Drug Product Manufacture For Use in Drug Substance Manufacture Other
Manufacturing and Analytical Characterization - Biomolecular	Integrated and Continuous Processing and Manufacturing	For Use in Drug Product Manufacture For Use in Drug Substance Manufacture Other
Manufacturing and Analytical Characterization - Biomolecular	Manufacture of Clinical Supplies	Blinding of Comparator Drugs Other Phase Appropriate GMP Speed to Patient
Manufacturing and Analytical Characterization - Biomolecular	Plant Engineering and Maintenance	Facility Design Legacy Facility Innovation/Renovation Media Media Fills Media/Buffer Preparation and Fluid Management Modeling and Scheduling Multiproduct Batch Plants Modular Manufacturing Other Plant Incident Investigations
Manufacturing and Analytical Characterization - Biomolecular	Process Design and Controls	Cleaning Validation Control of Impurity Formation In-Process Controls Other Process Analytical Technology and Parametric/Real-Time Process Modeling and Simulations Process Validation/Continuous Process Validation QbD and Assessment of Process Parameters Scale-Up/Process Transfers Statistical Process Controls and Six Sigma Use of Prior Knowledge and Risk-Based Approaches
Manufacturing and Analytical Characterization - Biomolecular	Single-Use and Disposable Systems	For Use in Drug Product Manufacture For Use in Drug Substance Manufacture Leachables and Extractables Other
Manufacturing and Analytical Characterization - Chemical	Analytical	Continuous/Real-Time Release Drug Release Measurement - Biorelevant Dissolution Drug Release Measurement - Cascade Impaction Drug Release Measurement - Dissolution Drug Release Measurement - Forms Drug Release Measurement - Other Excipients Impurities and Degradation - Forced Degradation Impurities and Degradation - Impurity Quantitation Impurities and Degradation - In Silico Predecision of Stability Impurities and Degradation - Other Method Development Strategies Model Maintenance New Analytical Technologies Other Physical Characterization Techniques Process Analytical Technology and Continuous Release Real Time Release testing
Manufacturing and Analytical Characterization - Chemical	Automation	Computer Validation Other
		Aseptic Technologies and Sterilization - Filling Aseptic Technologies and Sterilization - Filtration Aseptic Technologies and Sterilization - Mixing Aseptic Technologies and Sterilization - Other Bulk Packaging Freezing and Thawing Immunogenicity and Critical Quality Attributes

TRACK (SUBTRACK)	PRIMARY TOPIC	KEYWORDS
Manufacturing and Analytical Characterization - Chemical	Drug Product Manufacturing and Development	Liquids Manufacture - Oral and Topical Liquids Liquids Manufacture - Other Lyophilization and Drying Technologies Manufacturing and Assembly of Drug/Device Combinations Manufacturing of Aerosols and DPI Manufacturing of Drug Delivery Systems Other Primary Packaging - Blisters Primary Packaging - Bottles Primary Packaging - Container Closure Integrity Process Optimization Secondary Packaging Semi-solids Manufacture - Cremes Semi-solids Manufacture - Liposomes, Solid Lipid Nanoparticles Semi-solids Manufacture - Other Shipping Studies Solids Manufacture - Capsules Solids Manufacture - Drug Product Intermediates Solids Manufacture - Mini-tablets Solids Manufacture - Other Solids Manufacture - Powders Solids Manufacture - Tablets and Granules Storage Considerations Visual Inspection
Manufacturing and Analytical Characterization - Chemical	Drug Substance Manufacturing and Development	API Kilo Lab API Packaging and Storage Control of Impurity Formation Crystal Structure/Polymorph Screening Crystallization Development Filtration Genotoxic Impurities Immunogenicity and Critical Quality Attributes Milling and Micronization Technologies Other Particle Size Control Process Chromatography Process Optimization Purification
Manufacturing and Analytical Characterization - Chemical	General Aspects and Strategies	Change Control CMO Management Drug Master Files Drug Substance and Drug Product Shipment Electronic Records Handling Control Substances (DEA) Inspections and GMP Lean Manufacturing/Six Sigma/Operational Excellence Life Cycle Management Manufacturing Economics Materials Management and Warehousing Other Regulatory Strategy Supply Chain
Manufacturing and Analytical Characterization - Chemical	Generic Manufacturing	Other Patent Protection Pharmaceutical Equivalence Assessment
Manufacturing and Analytical Characterization - Chemical	Health, Safety, and Environment	Containment and Isolators Explosion Protection Green Chemistry High-Potent Drug Manufacturing OEL and PDE Other Solvent Recovery
Manufacturing and Analytical Characterization - Chemical	Innovative/Novel Processing Technologies and Concepts	For Use in Drug Product Manufacture For Use in Drug Substance Manufacture Other
Manufacturing and Analytical Characterization - Chemical	Integrated and Continuous Processing and Manufacturing	For Use in Drug Product Manufacture For Use in Drug Substance Manufacture Other
Manufacturing and Analytical Characterization - Chemical	Manufacture of Clinical Supplies	Blinding of Comparator Drugs Other Phase Appropriate GMP
Manufacturing and Analytical Characterization - Chemical	Plant Engineering, Equipment and Maintenance	Clean Media Facility Design Media Media Fills Modeling and Scheduling Multiproduct Batch Plants Modular Manufacturing Other Plant Incident Investigations
Manufacturing and Analytical Characterization - Chemical	Process Design and Controls	Cleaning Validation Control of Impurity Formation In-Process Controls Other Process Analytical Technology and Parametric/Real-Time Process Modeling and Simulations

TRACK (SUBTRACK)	PRIMARY TOPIC	KEYWORDS
Manufacturing and Analytical Characterization - Chemical	Process Design and Controls	<ul style="list-style-type: none"> Process Validation QbD and Assessment of Process Parameters Robustness/CPV Continuous Process Verification Scale-Up/Process Transfers Statistical Process Controls and Six Sigma Use of Prior Knowledge and Risk-Based Approaches
Manufacturing and Analytical Characterization - Chemical	Single-Use and Disposable Systems	<ul style="list-style-type: none"> For Use in Drug Product Manufacture For Use in Drug Substance Manufacture Leachables and Extractables Other
Preclinical, Clinical, and Translational Sciences	ADME	<ul style="list-style-type: none"> Biotransformation (In Vitro and In Vivo) High Throughput Assays Metabolite Identification and Characterization Metabolizing Enzymes Biotransformation (In Vitro and In Vivo) Novel Drug Modality/Novel Drug Delivery Optimization of Protein Design Other Payload-Linker Identification/Optimization Permeability, Distribution, and Site of Action Pharmacokinetics Screening Tools for Candidate Optimization Transporters Biotransformation (In Vitro and In Vivo)
Preclinical, Clinical, and Translational Sciences	Biology	<ul style="list-style-type: none"> Cell Therapy CAR-T, STEM Cell, Other Cellular and Molecular Pathways Gene Therapy In Silico In Vitro In Vivo Metabolizing Enzymes Omics Protein Binding Protein/Gene Engineering and Expression Receptor/Target Interactions Target Identification Transporter
Preclinical, Clinical, and Translational Sciences	Biomarkers	<ul style="list-style-type: none"> Clinical Qualification Disease Heterogeneity Assessments Endpoints (Surrogate, Primary, Secondary, Exploratory) High Content Data Analysis Novel Biomarkers Observational/Epidemiology Studies Patient Selection
Preclinical, Clinical, and Translational Sciences	Biostatistical Methodologies	<ul style="list-style-type: none"> Bayesian Methods Clinical Study Design Other Regulatory Recommendations Statistical Analysis Models Statistical Reporting Tools/Software
Preclinical, Clinical, and Translational Sciences	Clinical Trials	<ul style="list-style-type: none"> Designs and Methodology (Including QdB and RBM) Dosing Strategies Drug Interaction Studies Ethics in Clinical Trials Ex-US and Multi-national Studies Monitoring Other Patient Stratification Real World Evidence Regulatory Guidance Special Population Studies
Preclinical, Clinical, and Translational Sciences	Immunogenicity	<ul style="list-style-type: none"> Clinical Relevance Factor in Species Selection Immunogenicity Risk Assessment Impact on Exposure Impact on Safety Assessment Integrated Summary of Immunogenicity Post-Marketing Surveillance and REMS
Preclinical, Clinical, and Translational Sciences	Medicinal Chemistry	<ul style="list-style-type: none"> Combinatorial Chemistry Fragment Based Design In Silico Based Design Natural Products Novel Drug Modality Peptides and other Large Molecules Rational Drug Design Small Molecules Synthetic Chemistry
Preclinical, Clinical, and Translational Sciences	Modalities	<ul style="list-style-type: none"> ADCs Alternative Scaffold Bispecifics, Trispecifics and Higher Order Complexities CAR-T and Other Modified Cell Lines Cell-Based Therapy Encapsulated Drugs (Lipid, Nanoparticle, and Viral Vectors) Multispecific Antibodies Nanoparticle-Based Oligos, RNAs, and Locked Nucleic Acids

TRACK (SUBTRACK)	PRIMARY TOPIC	KEYWORDS
		Other PROTACs and Similar Molecular Glues Small Molecules Vaccines
Preclinical, Clinical, and Translational Sciences	Modeling and Simulation	Absorption Modeling Advanced Modeling Approaches Big Data and Artificial Intelligence Comparator Modeling Dose Project/Selection and Justification Drug interactions Imaging Based Approach In Vivo-In Vitro Correlation (IVIVC) Modeling Maternal/Fetal PK Model Other Other Special Populations Pediatric Model PK/PD Modeling Population PK Modeling Quantitative Systems Pharmacology (QSP) Resources, Tools and Software Standardization and Regulatory Advancement Translational Modeling
Preclinical, Clinical, and Translational Sciences	OMICS	Genomics Metabolomics Other Proteomics
Preclinical, Clinical, and Translational Sciences	Pharmaceutics	Drug Transport and Transporters Modeling and Simulation: New Approaches Molecular Biopharmaceutics Novel Drug Modality Pharmacokinetics
Preclinical, Clinical, and Translational Sciences	Pharmacology	Behavioral Pharmacology Cell Death and Differentiation DNA Damage and Repair Drug Abuse Drug-Drug Interactions Epigenetics and Epigenetic Therapy Experimental Therapeutics Gene Therapy Immunotherapy and Immunopharmacology Natural Products Neuropharmacology Omics (genomics, metabolomics, epigenomics, proteomics) Oncology (hematologic malignancies) Oncology (solid tumors) Orphan Drugs and Rare Diseases Pharmacokinetics Quantitative Pharmacology Signal Transduction Systems Pharmacology Toxicology Vaccines
Preclinical, Clinical, and Translational Sciences	Regulatory Guidance/Submissions	Clinical Study Reports (CSRs) Clinical Trial Protocols Data Standards and Management (Including CDISC) Harmonization and Guidance Documents Health Authority Interactions/Meetings Labeling Other Regulatory Filings and Submissions Safety
Preclinical, Clinical, and Translational Sciences	Safety	Cellular and Molecular Toxicology De-risking Strategies Genetic Toxicity Immuno-toxicity IND Enabling Studies Mechanistic Toxicity Other Screening Toxicity Studies
Preclinical, Clinical, and Translational Sciences	Translation	Drug-Drug Interaction (DDI) Formulation Selection Human PK and Dose Projections Other Patient Selection PK/PD Safety
Preclinical, Clinical, and Translational Sciences	Type of Human Studies	Adaptive and Accelerated Designs Bioequivalence Biosimilars Diseased Patient Population Studies Drug-Drug Interaction (DDI) First-Time-in-Human (FTIH) Food Effect Geriatric Organ Impairment

TRACK (SUBTRACK)	PRIMARY TOPIC	KEYWORDS
		Other Other Special Populations Pediatric Pregnant Women Radio-Labeled Mass Balance, Microdose and ADME Registrational Studies and Strategies Relative and Absolute Bioavailability Thorough QT/QTc (TQT)